Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention

NCT07133074 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT07133074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07133074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 4
Overall status
Recruiting
Start date
April 20, 2026
Completion date
November 30, 2029
Enrollment
3,800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

beta lactam allergy, hematologic malignancy